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Inhibition of atypical protein kinase C‑ι effectively
reduces the malignancy of prostate cancer cells by
downregulating the NF-κB signaling cascade
ANDRÉ H. APOSTOLATOS1*, WISHRAWANA S. RATNAYAKE1*, HLA WIN-PIAZZA1,
CHRISTOPHER A. APOSTOLATOS1, TRACESS SMALLEY1, LOVELEEN KANG1,2,
RAOUL SALUP1,2, ROBERT HILL3 and MILDRED ACEVEDO-DUNCAN1
1

Department of Chemistry, University of South Florida, Tampa, FL 33620; 2The James A. Haley V. A. Hospital,
Tampa, FL 33612; 3Department of Cell Biology, Microbiology and Molecular Biology,
University of South Florida, Tampa, FL 33620, USA
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Abstract. Prostate cancer (PC) is the most common type of
cancer among men. Aggressive and metastatic PC results in lifethreatening tumors, and represents one of the leading causes of
mortality in men. Previous studies of atypical protein kinase C
isoforms (aPKCs) have highlighted its role in the survival of
cultured prostate cells via the nuclear factor (NF)-κ B pathway.
The present study showed that PKC‑ι was overexpressed in PC
samples collected from cancer patients but not in non-invasive
prostate tissues, indicating PKC‑ι as a possible prognostic
biomarker for the progression of prostate carcinogenesis.
Immunohistochemical staining further confirmed the association between PKC‑ι and the prostate malignancy. The DU‑145
and PC‑3 PC cell lines, and the non-neoplastic RWPE‑1
prostatic epithelial cell line were cultured and treated with
aPKC inhibitors 2‑acetyl‑1,3-cyclopentanedione (ACPD) and
5-amino‑1-(1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)‑1H-imidazole-4-carboxamide (ICA‑1). Western blot data demonstrated
that ICA‑1 was an effective and specific inhibitor of PKC‑ι and
that ACPD inhibited PKC‑ι and PKC‑ζ. Furthermore, the two
inhibitors significantly decreased malignant cell proliferation
and induced apoptosis. The inhibitors showed no significant
cytotoxicity towards the RWPE‑1 cells, but exhibited cytostatic effects on the DU‑145 and PC‑3 cells prior to inducing
apoptosis. The inhibition of aPKCs significantly reduced the
translocation of NF-κ B to the nucleus. Furthermore, this inhi-

Correspondence to: Dr Mildred Acevedo-Duncan, Department of

Chemistry, University of South Florida, 4202 East Fowler Avenue,
CHE 205, Tampa, FL 33620, USA
E-mail: macevedo@usf.edu

*

Contributed equally

Key words: protein kinase C‑ι, atypical protein kinase C inhibitors,
prostate cancer, nuclear factor-κ B, biomarkers

bition promoted apoptosis, reduced signaling for cell survival,
and reduced the proliferation of PC cells, whereas the normal
prostate epithelial cells were relatively unaffected. Overall, the
results suggested that PKC‑ι and PKC‑ζ are essential for the
progression of PC, and that ACPD and ICA‑1 can be effectively used as potential inhibitors in targeted therapy.
Introduction
The American Cancer Society estimates that 164,690 new
cases of prostate cancer (PC) will be diagnosed in 2018. PC is
the third leading cause of cancer-associated mortality among
American men, following lung and colorectal cancer. It is
estimated that ~1/7 men are diagnosed with the disease during
their lifetime, with 1/39 succumbing to the disease (1).
The most common treatments for PC include radiation
therapy, chemotherapy and hormone therapy. Radiation
therapy is not always ideal as healthy living cells are damaged
by the treatment, causing numerous side effects in patients.
Hormone therapy requires surgical castration and the use of
anti-androgens, which also have side effects and affect the
patient's lifestyle (2). In addition to the side effects that follow
hormone therapy, patients often become castration-resistant,
meaning the cancer is no longer affected by the treatment (2).
Once this occurs, chemotherapeutics, including docetaxel, are
used. Docetaxel only increases a patient's survival rate by ~3
months. This is largely due to resistance that develops within
the cancer cells (3).
The protein kinase C (PKC) family of isozymes transduce
signals and control other proteins through phosphorylation (4).
The PKC family comprises 14 known isozymes, which are
found in varying ratios in the cytoplasmic and membrane fraction of cells depending on the type of tissue and its physiological
state (5). PKC isozymes can be classified into three groups.
Group I includes Ca2+-dependent isozymes: cPKC‑α, cPKC‑βl,
cPKC‑ βll, and cPKC‑ γ. Isozymes in Group II (nPKC‑ δ,
nPKC‑ε, nPKC‑η and PKC‑θ) are Ca2+-independent. Group III
includes the atypical (a)PKCs, including aPKC‑ι (6), aPKC‑ζ,
aPKC‑ζll (7) aPKC‑µ (protein kinase D) and aPKC‑ν (8), which
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are insensitive to diacylglycerol and calcium and do not bind to
or become activated by phorbol esters. PKC regulates cellular
functions, metabolism and proliferation by phosphorylating
proteins in response to transmembrane signals from hormones,
growth factors, neuro-transmitters, and pharmacological
agents. The activation of PKC by various agonists, including
radiation, results in the altered transcription of a considerable number of genes. PKCs are involved in the day-to-day
functioning of normal cells, however, they can cause several
adverse effects when disrupted. PKC is the major receptor
for tumor-promoting phorbol esters, however, the extent to
which PKC is involved in cellular malignancy remains to be
fully elucidated. Various studies have indicated that increased
tumorigenicity results from either the dysregulation of PKC
activity, changes in PKC concentration, or both (9‑13).
PKC isozymes have been implicated in carcinogenesis,
however, investigation of the functional significance of these
enzymes in human cancer has been limited so far. PKC
isozymes α, β, δ, ε, γ, η, ζ, ι, and µ are expressed in the normal
and cancerous prostate (14). LNCaP cells are a widely used
model for investigation of PC. Besides classical PKC‑α, the
novel PKC‑δ is overexpressed in LNCaP cells and provokes
phorbol ester-induced apoptosis. In PC‑3 and DU‑145 cells,
PKC‑δ is involved in the cell motility and invasion of prostate
tumor cells (15,16). In addition, PKC‑ε alongside Akt promotes
matrix adhesion-containing actin-filaments and β-intergins in
recurrent PC cells (15). In DU‑145 cells, the downregulation
of PKC‑ε prevents apoptosis (16). Therefore, PKC‑ε may be
targeted for prostate therapy. Finally, the PKC‑µ and PKC‑ζ
mammalian target of rapamycin (mTOR)/p70 S6 kinase
pathway is associated with the progression of androgendependent PC to androgen-independent PC (17‑19). Therefore,
understanding PKC isoforms in PC may contribute to possible
novel diagnostic and therapeutic strategies.
PKCs is involved in tumor growth and formation when the
levels of PKC are markedly altered (5). PKC‑ι is a member of
the PKC family located in chromosome 3 at 3q26.2, and is a
human oncogene. PKCs can be overexpressed in various types
of cancer, including ovarian, lung, head and neck cancer, and
PC (20-22). Elevated levels of PKC‑ι have been correlated with
poorer prognosis. It was found that patients with lung cancer
who had elevated levels of PKC‑ ι during the early stages
were 10 times more likely to succumb to mortality from the
disease, compared with those who had low levels of PKC‑ι.
PKC‑ι is also involved in several oncogenic signaling pathways (23). For these reasons, the in vitro effects of two novel
aPKC inhibitors, 5-amino‑1-(1R,2S,3S,4R)-2,3-dihydroxy4-methylcyclopentyl)‑1H-imidazole-4-carboxamide (ICA‑1)
and 2‑acetyl‑1,3-cyclopentanedione (ACPD), on the normal
RWPE‑1 cell line, and the DU‑145 and PC‑3 PC cell lines,
were investigated in the present study. ICA‑1 has been shown
to target PKC‑ ι, whereas ACPD has been shown to target
PKC‑ι and PKC‑ζ (24,25).
The nuclear factor (NF)-κ B signaling pathway is involved
in cancer propagation and dissemination in several types of
cancer, however, its involvement in PC remains to be fully
elucidated. The inhibitor of NF-κ B kinase (IKK) complex is
comprised of IKKα and IKKβ, both of which are necessary for
the activation of NF-κ B. In the present study, it was hypothesized that PKC‑ι acts on IKKα /β, causing the release and
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translocation of NF-κ B. Inhibition of this pathway following
treatment with ICA‑1 is expected allow normal apoptosis to
take place with minimal effect on RWPE‑1 cells, but with
more marked effects in DU‑145 and PC‑3 cells.
The results of the present study showed a correlation
between the presence of PKC‑ι and PC. It also revealed the
efficacy of ACPD and ICA‑1 on PKC‑ι and indicated the role
of PKC‑ι in the survival of PC. Cumulatively, the results led
to the conclusion that the detection of PKC‑ι may be used as a
biomarker of prostate carcinogenesis and that PKC‑ι inhibition
may be an alternative therapy in patients with PC.
Materials and methods
ICA‑1 was synthesized by Therachem Research Medilab
(Jaipur, India) and ACPD was purchased from Sigma-Aldrich;
EMD Millipore (Billerica, MA, USA). The inhibitors were
dissolved in sterile distilled water prior to use. Dulbecco's
phosphate-buffered saline without Mg2+ and Ca 2+ (DPBS)
was purchased from the American Type Culture Collection
(Manassas, VA, USA). Trypsin-ethylenediaminetetraacetic
acid (EDTA) solution was purchased from Thermo Fisher
Scientific, Inc. (Waltham, MA, USA). Polyclonal primary
antibodies were purchased from the following companies:
Anti-PKC‑ι mouse monoclonal (cat. no. 610176) and B-cell
lymphoma 2 (Bcl-2; cat. no. 610538) from BD Transduction
Laboratory (Lexington, KY, USA). PKC‑ζ (cat. no. sc‑17781),
NF- κ B p65 (cat. no. sc-372-G), inhibitor of NF- κ B α
(Iκ Bα; cat. no. sc‑1643), phosphorylated (phospho) Iκ Bα
(cat. no. sc-8404) β -actin (cat. no. sc‑1616) goat polyclonal,
PKC‑α (cat. no. sc-8393) mouse monoclonal, cytochrome c
(cat. no. sc‑13156), survivin (cat. no. sc‑17779) and caspase‑3
(cat. no. sc-7272) from Santa Cruz Biotechnology Co., Ltd.
(Santa Cruz, CA, USA), phosphorylated phosphatase and
tensin homolog (PTEN; S380; cat. no. 9551), phosphorylated AKT (S473; cat. no. 4059S), phosphorylated IKKα /β
(S176/180; cat. no. 2697), poly (ADP-ribose) polymerase
(PARP; cat. no. 9532) and cleaved-PARP (cat. no. 9185)
from Cell Signaling Technology Inc. (Danvers, MA, USA).
β -catenin (cat. no. ab16051) from Abcam (Cambridge,
MA, USA). Secondary antibodies were purchased from the
following companies: Horseradish peroxidase (HRP) goat
x mouse IgG (cat. no. JGM035146), HRP goat x rabbit IgG
(cat. no. JGZ035144) from Accurate (Westbury, NY, USA);
HRP bovine anti-goat IgG (cat. no. sc-2350 from Santa Cruz
Biotechnology, Inc.. The RWPE‑1 (ATCC® CRL‑11609™)
epithelial cells and DU‑145 (ATCC® HTB-81™) human prostate carcinoma cells were purchased from the American Type
Culture Collection. The PC‑3 cells were acquired from Moffitt
Cancer Center (Tampa, FL, USA).
Prostate tissue analysis. The protein for western blot analysis
was extracted from human biopsy-derived benign prostate
hyperplasia (BPH) tissues obtained from the Cooperative
Human Tissue Network (Southern Division) at the University
of Alabama (Birmingham, AL, USA). For the purposes
of the present study, BPH was defined as a non‑cancerous
enlargement of the prostate gland. The BPH tissue samples
were obtained from men of varying ages (57-80 years old)
with a mean age of 67.6 years. Protein extraction from the
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fresh-frozen radical prostatectomy samples of patients with
PC were obtained during surgery performed at the James A.
Haley Veterans Hospital (Tampa, FL, USA) between May and
August 2007. All patients provided informed consent as part of
a clinical protocol approved by the Institutional Review Board
(IRB no. 103023) of the University of South Florida (Tampa,
FL, USA). The samples were placed on ice immediately
following prostatectomy and were frozen in liquid nitrogen
within 30-60 min post-prostatectomy. The prostate tissues
(0.5‑1 g) were re-suspended and sonicated in 2 ml homogenization buffer containing 50 mM HEPES (pH 7.5), 150 mM NaCl,
0.1% Tween-20, 1 mM ethylenediamine-tetraacetic acid, 2 mM
ethylene glycol bis(β-aminoethyl ether)-N,N,N', N',-tetraacetic
acid, 0.1 mM orthovanadate, 1 mM NaF, 2 mM phenyl-methylsulfonly fluoride, 2.5 µg/ml leupeptin, 1 mM dithiothreitol and
0.15 U/ml aprotinin. The suspension was sonicated for three
15 sec cycles on ice. The prostate tissue suspensions or cell
lysates were centrifuged at 40,000 g for 30 min at 4˚C to obtain
cell extracts. The proteins were quantified according to the
Bradford method (26). Tissue extracts containing equal quantities of protein in each lane were run on 10% SDS-PAGE gels
according to Laemmli (27) and the proteins were transblotted
on nitrocellulose membrane according to Towbin et al (28). The
tissue lysates (100 µg) were used for western blot analysis with
antibodies against PKC‑α (10 µg, 1:500 dilution), PKC‑ι (5 µg,
1:4,000 dilution) and β-actin (10 µg, 1:500 dilution) and incubated for a duration of 1 h at room temperature. The secondary
antibodies, obtained from Accurate (cat. nos. JGM035146 and
JG2035744) were used at a dilution of 1:15,000 (1 µg) and
incubated for 2 h at room temperaure. The blots were subjected
to chemiluminescence and results were captured on X-ray film
and developed by machine. Observable bands were scanned
and quantified by densitometry analysis. The specimens used
were from 10 patients with PC (one core with adenocarcinoma
from each patient), eight patients with high grade prostate
intraepithelial neoplasma (HGPIN; 1 core with HGPIN from
each patient) and nine patients with BPH (1 core with from each
patient), comprising a total of 27 samples. Samples obtained
from cell cultures and examined by western blot analysis and
were visualized digitally by the Protein Simple (San Jose, CA,
USA) FlourChem system and analyzed with the accompanying
alpha viewer software.
Immunohistochemical staining. For immunohistochemistry
(IHC), de-identified, archival, unstained sections of full-core
prostate needle biopsies (PNBs) were used, which were obtained
for diagnostics in the systematic PC screening program at the
James A. Haley Veterans Administration Medical Center. The
PNB specimens examined were from 10 patients with PC
(1 core with adenocarcinoma from each patient), eight patients
with HGPIN (1 core with HGPIN from each patient) and nine
patients with BPH (1 core with from each patient), comprising
a total of 27 samples. Following the deparaffinization of the
sections, and citrate microwave antigen retrieval, blocking
was performed. For the detection of PKC‑ α, the sections
were incubated with monoclonal anti-PKC‑α antibody (1:100
dilution; BD Transduction Laboratories) for 60 min at room
temperature, followed by washing and detection with the
‘EnVision’ detection system using mouse IgG polymer and
DAB chromogen. For the detection of PKC‑ι, separate sections

were subsequently incubated overnight with purified mouse
monoclonal anti-PKC‑ ι (1:200 dilution; BD Transduction
Laboratories), followed by washing and a subsequent 30-min
incubation at room temperature with 1:200 rat anti-mouse
IgG2b. Final detection was performed using DAB chromogen.
All sections were examined for PKC‑α and PKC‑ι and scored
using the Allred semi-quantitative scoring system (29). The
Allred score is a composite of the percentage of cells stained
and the intensity of their staining. The percentage of cells
stained, termed the proportion score, is classified between 0
and 5. The intensity of the cells stained is termed the intensity score and it is rated as 1, 2 or 3; thus, composite scores
range between 0 and 8, with 0 being the lowest and 8 being
the maximum score. The adenocarcinoma glands, glands with
HGPIN, BPH glands, and stromal cells were scored separately
using a microscope (Olympus, Tokyo, Japan).
Cell culture. The cells were grown as a monolayer in a T25
tissue culture flask with 5 ml of growth medium and were
maintained in a 37˚C incubator with 5% CO2. The E-MEM
and F‑12 growth media were obtained from American Type
Culture Collection. The medium was supplemented with
10% fetal bovine serum (FBS) and a mix of the antibiotics
penicillin (10,000 IU) and streptomycin (10,000 µg/ml) in a
100X concentration purchased from Corning Life Sciences
(Tewksbury, MA, USA).
Cell proliferation assay. The RWPE‑1, DU‑145 and PC‑3
cells were cultured in T25 cell culture flasks with 20,000 cells
seeded into each. The flasks were treated with either ICA‑1 or
ACPD at doses of 1, 5, and 10 µM, in addition to an untreated
control set for each. The treatment was repeated over the
course of 72 h and samples were taken at 24-h intervals. The
cells were trypsinized and placed into a 1.5 ml microcentrifuge
tube at intervals of 24, 48, and 72 h. The tubes were inverted
gently to maintain solution homogeneity and cell numbers
were measured using a Cell Scepter counter (EMD Millipore).
4-[3-(4-iodophenyl)-2-(4-nitropheny))-2H-5-tetrazolio]‑1,3benzene disulfonate (WST‑1) assay for cell viability and
cytotoxicity. The WST‑1 assay (in vitro) was performed by
culturing ~4x103 cells/well (RWPE‑1, DU‑145 and PC‑3 cells)
in a 96-well plate. After 24 h, fresh media were supplied
(200 µl/well) and the cells were treated with either an equal
volume of sterile water (vehicle control) or with 10 µM of
ICA‑1 or 10 µM of ACPD, which was identified as the optimal
working concentration for the PC cell lines for the two inhibitors. Additional doses were supplied every 24 h during a 3-day
incubation period. At the end of day 3, media were removed and
fresh media (100 µl) were added with WST‑1 reagent (10 µl)
to each well. The absorbance was measured at 450 nm every
1 h up to 8 h using the Synergy HT microplate reader from
Biotek Instruments, Inc., (Winooski, VT, USA). The detailed
procedure was performed as described by Ratnayake et al (30).
Cell sub-fractionation. The DU‑145 and PC‑3 cells were
cultured in a T25 cell culture flasks (20,000 cells seeded into
each). The flasks were treated with either ICA‑1 or ACPD at a
dose 10 µM, with an untreated control set for each. The treatment was repeated over the course of 72 h and samples were
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Figure 1. Expression of PKC‑α and PKC‑ι in prostate tissues. Tissue extracts (100 µg) of (A) BPH and (B) PC were immunoblotted for PKC‑α and PKC‑ι. All
patient tissues were maintained in liquid nitrogen and processed the same day of collection. BPH tissues showed minimal to no expression of PKC‑ι. PC tissues
showed overexpression of PKC‑ι compared to BPH tissues (*P=0.00048). Western blot analysis for β-actin demonstrated equal loading of each sample. Three
trials were performed in triplicate. BPH, benign prostate hyperplasia; PC, prostate cancer; PKC, protein kinase C; N, normal; M, malignant.

taken at 24-h intervals. At 30 min prior to harvesting, the cells
were exposed to 10 nM of tumor necrosis factor (TNF)‑ α.
The NE-PER Nuclear and Cytoplasmic Extraction kit from
Thermo Fisher Scientific, Inc. was used to harvest the proteins
and separate the nuclear protein from the cytoplasmic protein.
Flow cytometry for the analysis of apoptosis. The DU‑145
and PC‑3 cells (40,000 cells/flask) were cultured in a T25
cell culture flasks. The flasks were treated with either ICA‑1
or ACPD at a dose 10 µM, with an untreated control set for
each. After 24 h, the media were removed and dead cells
were collected by centrifugation using 350 x g for 4 min at
4˚C. The cells were washed twice with ice-cold DPBS (1X)
prior to lifting with trypsin and trypsin was neutralized with
an equal volume of media. The cells were then combined
with the collected dead cells and washed twice with icecold DPBS (1X). A PE Annexin V apoptosis detection kit
(BD Biosciences, Pharmingen, San Jose, CA, USA) was used
to detect the apoptosis according to the detailed protocol
provided by BD Pharmingen. The BD Accuri™ C6 Plus
personal flow cytometer instrument was used to analyze the
samples. Three replicate experiments were performed.
Statistical analysis. All values are presented as the mean ± standard deviation (n=3, where n is a single trial and each trial
contained 9-24 replicates). Statistical analysis was performed
with Student's t-test or one-way analysis of variance followed
by Tukey's multiple comparison tests using the ‘VassarStats’
web tool (vassarstats.net) for statistical analysis. P≤0.05 was
considered to indicate a statistically significant difference.
Results
The association between the absence of PKC‑ι in BPH tissue
and its robust presence in PC is shown in Fig. 1. PKC‑ι was
abundant in all PC tissues. PKC‑ α (positive control PKC)

and PKC‑ι were identified in western blot analysis by bands
with molecular weights of 80 and 74 kDa, respectively, which
corresponded to the immunoreactive signal obtained from
U-373MG glioma cells, which contain PKC‑ ι and PKC‑ α
(data not shown). The western blot controls for PKC‑α did not
show a pattern of expression specific to BPH, or malignant
prostate tumors. β -actin was used as the internal control to
ensure equal quantities of protein loaded in to each well of
the SDS-PAGE gel. A 100‑fold increase in PKC‑ι immunoreactivity was detected in PC tissue when compared with BPH
tissue (Fig. 1A and B). The level of PKC‑ι in the BPH tissue
differed significantly from that in the PC tissue (P=0.00048).
This demonstrated that PKC‑ι was significantly overexpressed
in PC tissues compared with BPH tissues.
Subsequently, IHC was performed to investigate comparatively the tissue distribution and intracellular localization
of PKC‑ ι and PKC‑ α. The IHC data showed that PKC‑ α
was expressed in the stromal cells but showed minimal to
no expression in the majority of the BPH (Fig. 2A), HGPIN
(Fig. 2B) or PC (Fig. 2C) glands. In only one case did the PC
glands show moderate expression of PKC‑α. In that case the
PC glands expressing PKC‑α were Gleason pattern 4 (Table I),
which may explain the increase of PKC‑α.
By contrast, the expression of PKC‑ ι was noted in all
glands, with a proportion score of 5 in the majority of cases
(Table I and Fig. 2D-F), however, the intensity of staining was
more marked in the PC glands with Allred scores of +8 and +7
(Table I and Fig. 2F), compared with that in the BPH glands
(Fig. 2D) and glands with HGPIN (Table I and Fig. 2E). The
BPH glands showed similar weak staining in samples obtained
from patients with and without prostatic adenocarcinoma. The
stromal cells showed weak to moderate staining in samples
with and without adenocarcinoma. PKC‑ι was present at low
levels in a comparative number of the BPH samples, however,
the intensity was markedly increased in the adenocarcinoma
samples, resulting in higher composite scores. Overall, the IHC
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Figure 2. Immunohistochemical staining of PKC‑α and PKC‑ι in BPH, HGPIN and PC. Tissue was stained with PKC‑α antibody as a control for PKC‑ι
staining. Results show PKC‑ι staining in (A) BPH, (B) HGPIN, and (C) PC tissue. PKC‑α staining is shown in (D) BPH glands, (E) glands with HGPIN, and
(F) PC glands. Tissues examined comprised BPH (n=9), HGPIN (n=8) and PC tissues (n=10). Magnification for all micrographs was x400. Three experiments were performed in triplicate. BPH, benign prostate hyperplasia; HGPIN, high grade prostate intraepithelial neoplasma; PC, prostate adenocarcinoma;
PKC, protein kinase C.

Table I. PKC‑α and PKC‑ι staining of glands and stroma of patients with BPH, HGPIN and prostate adenocarcinoma.
Staining (No. of cases)a
	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Total cases
PKC‑α
8+
7+
6+
5+
4+
3+
2+
1+
0
BPH
9
HGPIN
8
Adenocarcinoma
10

Glands
Stroma
Glands
Stroma
Glands
Stroma

0
0
0
0
0
0

0
1
0
1
0
1

0
2
0
3
1
4

0
5
0
4
0
2

0
1
0
0
1
1

0
0
0
0
0
0

5
0
3
0
4
2

0
0
0
0
0
0

4
0
5
0
4
0

Staining (No. of cases)a
	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Total cases
PKC‑ι
8+
7+
6+
5+
4+
3+
2+
1+
0
BPH
9
HGPIN
8
Adenocarcinoma
10

Glands
Stroma
Glands
Stroma
Glands
Stroma

0
0
1
0
9
0

2
0
3
0
1
0

7
0
3
0
0
0

0
2
1
0
0
3

0
4
0
3
0
5

0
2
0
4
0
2

0
1
0
1
0
0

0
0
0
0
0
0

0
0
0
0
0
0

Staining based on the Allred score (26). PKC, protein kinase C; BPH, benign prostate hyperplasia; HGPIN, high grade prostate intraepithelial
neoplasma; PC, prostate adenocarcinoma.

a

data from the PNB specimens confirmed the higher expression
of PKC‑ι in PC detected in the western blot analysis from fresh
frozen excisional clinical prostate tissue specimens.

To establish whether ACPD or ICA‑1 affected PKC‑ ι
and PKC‑ζ, their protein levels were determined by western
blot analysis. In the malignant cells (DU‑145 and PC‑3),
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Figure 3. Effects on PKC‑ι regulation and apoptosis. Effects on PKC‑ι and apoptosis were examined following inhibition of PKC‑ι with either ICA‑1 (10 µM) or
ACPD (10 µM) for 72 h with respect to their controls. Protein expression of PKC‑ι, PKC‑ζ, caspase 3, Bcl-2, PARP, cytochrome c, and survivin in the RWPE‑1
cell line and the DU‑145 and PC‑3 malignant cell lines. A total of 35 µg protein was loaded into each well and results were normalized by β-actin. Three trials
were performed in triplicate. Densitometry bar graphs show the percentage change of the treated sample with respect to their controls (mean ± standard deviation). *P≤0.05, vs. control. PKC, protein kinase C; Bcl-2, B-cell lymphoma 2; PARP, poly (ADP-ribose); ACPD, polymerase; 2‑acetyl‑1,3-cyclopentanedione;
ICA‑1, 5-amino‑1-(1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)‑1H-imidazole-4-carboxamide.

there was an abundance of PKC‑ι (Fig. 3) compared with the
normal cells (RWPE‑1). There was a marginal difference in
the RWPE cells, however, neither drug reduced the levels of
PKC‑ι significantly (P=0.077). The effects were more marked
in the DU‑145 cells. ICA‑1 inhibited PKC‑ι and, following
3 days of treatment, there was a decrease of 64% (P=0.01)
in PKC‑ι. Following 3 days of treatment with ACPD, which
inhibits PKC‑ι and PKC‑ζ, there was an average decrease of
51% (P=0.018) in PKC‑ι. In the PC‑3 cells, there was a 40%
(P=0.028) decrease in PKC‑ι following treatment with ICA‑1
and a 37% (P=0.036) decrease in PKC‑ι following treatment
with ACPD. ICA‑1 had no significant effect on the levels of

PKC‑ζ in any of the cell lines, whereas ACPD had a significant
effect, reducing the levels of PKC‑ζ by 23% (P≤0.05), in the
PC‑3 cells only.
To determine whether ICA‑1 or ACPD induced apoptosis, the apoptotic markers caspase‑3, Bcl-2, PARP, cleaved
PARP, survivin and cytochrome c were used to detect
ongoing apoptosis in the cell lines (Fig. 3). In all three cell
lines treated with ICA‑1 and ACPD, there was a measurable
increase in apoptosis. Following ICA‑1 treatment for 72 h, the
RWPE‑1 control line showed no significant change in either
cytochrome c or survivin. Following treatment with ACPD
for 72 h, the RWPE‑1 cells showed no significant change in
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Figure 4. Effects of ICA‑1 or ACPD on cell populations in a 72-h period. Populations of cells under normal conditions (red) and under treatment with either
10 µM ICA‑1 (blue) or 10 µM ACPD (yellow) in (A) RWPE‑1, (B) DU‑145, and (C) PC‑3 cell lines. Effects of ICA‑1 and ACPD on in vitro cytotoxicity over 8 h
were measured by absorbance in nm under normal conditions (red) and under the effects of either 10 µM ICA‑1 (blue) or 10 µM ACPD (yellow), in (D) RWPE‑1,
(E) DU‑145, and (F) PC‑3 cell lines. There were 24 replicates per sample performed over three trials. ACPD, polymerase; 2‑acetyl‑1,3-cyclopentanedione;
ICA‑1, 5-amino‑1-(1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)‑1H-imidazole-4-carboxamide.

cytochrome c or in survivin. By contrast, the DU‑145 cell
line showed a more substantial change, with an almost 3‑fold
increase in cytochrome c and a reduction in survivin by 50%
following treatment of ICA‑1. Following treatment with ACPD
for 72, the DU‑145 cells showed ~400% (P<0.001) increase in
cytochrome c and a 50% (P=0.015) decrease in survivin. In
the PC‑3 cells treated with ICA‑1, there was a 2‑fold increase
in cytochrome c (P=0.011) and a 40% decrease in survivin
(P=0.028). The PC‑3 cells treated with ACPD showed a 150%
(P=0.013) increase in cytochrome c and a 35% decrease in
survivin (P=0.042). The levels of caspase-3 and cleaved-PARP
were significantly increased and those of Bcl-2 and total PARP
were significantly reduced upon inhibitor treatment in the PC
cell lines. All cell lines were also probed with β-actin to ensure
equal loading between lanes.
The effects of ICA‑1 (10 µM) and ACPD (10 µM) on
cell proliferation were also determined (Fig. 4A-C). There
was a noticeable but statistically insignificant effect of the
inhibitors ICA‑1 and ACPD on the RWPE‑1 cell line. Both
inhibitors retained >90% of the cell population present in
the untreated RWPE‑1 cells (Fig. 4A). By contrast, there
was a substantial decrease in the population of DU‑145 cells
treated with the inhibitors ICA‑1 (P≤0.01) and ACPD (P≤0.01)
(Fig. 4B). The PC‑3 cells showed a similar trend of population
decline following treatment with ICA‑1 (P=0.01) and ACPD
(P=0.0052) (Fig. 4C).
To determine the in vitro cytotoxicity of ICA‑1 and ACPD
on normal and malignant cell lines, a WST‑1 assay was
performed. ICA‑1 and ACPD demonstrated no significant
cytotoxicity towards the normal prostate epithelial RWPE‑1
cell line (Fig. 4D). As shown in Fig. 4E and F, ICA‑1 exhibited
significant cytotoxicity (P≤0.05) on the two metastatic prostate
cancer cell lines (DU‑145 and PC‑3). These results indicated
that ICA‑1 and ACPD appeared to be cytostatic more than
cytotoxic in the time range assessed, thereby retarding PC cell
growth and proliferation.

Figure 5. Flow cytometric analysis of PE Annexin V staining for prostate
cancer cells. Graphs show fluorescent emission of PC‑3 cells in the (A) control,
(B), ICA‑1- and (C) ACPD-treated groups, and DU‑145 cells in the (D) control, (E) ICA‑1- and (F) ACPD-treated groups. Cells were incubated with PE
Annexin V (x-axis) against 7AAD (y-axis). Cells were treated with ICA‑1 and
ACPD with respective IC50 concentrations for 24 h and 50,000 events were
analyzed and recorded to obtain FL3-A (PE-Annexin V), vs. FL-2A (7-AAD).
Three experiments were performed with 24 replicates and representative
plots are shown. ACPD, polymerase; 2‑acetyl‑1,3-cyclopentanedione; ICA‑1,
5-amino‑1-(1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)‑1H-imidazole4-carboxamide; 7AAD, 7-amino-actinomycin; Ctrl, control.
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Figure 6. Effects of 10 µM ICA‑1 and 10 µM ACPD on NF-κ B translocation in RWPE‑1, DU‑145, and PC‑3 cells. Protein expression of NF-κ B p65 is shown in
nuclear and cytoplasmic cell fractions following 72 h of treatment. Cells were exposed to 10 nM of TNF‑α 30 min prior to harvest to induce NF-κ B translocation. Other targets in the proposed pathway and targets known to be affected by PKC‑ι activation were assessed, including pIKKα/β, IKKα/β, pIκ Bα, Iκ Bα,
β-catenin, pPTEN, and pAKT. A total of 50 µg protein was loaded into each well and the results were normalized by β-actin. Three trials were performed
in triplicate. Densitometry bar graphs are shown as the percentage change of the treated sample with respect to their controls (mean ± standard deviation).
*
P≤0.05, vs. control. NF-κ B, nuclear factor-κ B; Iκ Bα, inhibitor of NF-κ Bα; IKK, Iκ Bα kinase; PTEN, phosphatase and tensin homolog; p, phosphorylated;
ACPD, polymerase; 2‑acetyl‑1,3-cyclopentanedione; ICA‑1, 5-amino‑1-(1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)‑1H-imidazole-4-carboxamide.

As shown in Fig. 5, flow cytometric analysis of apoptosis
showed that PC‑3 viability decreased from 91.8% (Fig. 5A)
to 60.8% following ICA‑1 treatment (Fig. 5B) and 60.9%
following ACPD treatment (Fig. 5C). Early apoptosis increased
from 6.8% (Fig. 5A) to 37.3 and 36.3% following ICA1 and
ACPD treatments, respectively. By contrast, the DU‑145
cells showed a marginally lower response, in which viability
decreased from 97.9% (Fig. 5D) to 89% following ICA‑1 treatment (Fig. 5E) and 85.5% following ACPD treatment (Fig. 5F).
Early apoptosis increased from 0.9% (Fig. 5D) to 3.4 and 2.6%
following ICA‑1 and ACPD treatments, respectively (Fig. 5E
and F). The late stage of apoptosis significantly increased from
1.2% (Fig. 5D) to 7.6 and 12% for ICA‑1 and ACPD treatments,
respectively, in the DU‑145 cell line (Fig. 5E and F).

Subsequently, the present study determined whether ICA‑1
or ACPD affected cell survival by inhibiting the translocation of NF-κ B from the cytoplasm to the nucleus (Fig. 6).
Following exposure to TNF‑α, the protein levels of NF-κ B
were measured in the nucleus and the cytosol of DU‑145 and
PC‑3 cells. Following treatment with ICA‑1, there was a 5-fold
decrease in nucleic NF-κ B in the DU‑145 cells (P=0.02) and a
3‑fold decrease of nucleic NF-κ B in the PC‑3 cells (P=0.025),
compared with the untreated samples. With ACPD, there was
a 1.5‑fold decrease in nucleic NF-κ B (P=0.046) in the DU‑145
cells and a 40% decrease in NF-κ B (P=0.028) in the PC‑3
cells, compared with the untreated samples (Fig. 6). In addition, the phosphorylation of IKKαβ (S176/180) and Iκ Bα (S32)
were examined, both of which reduced significantly (P≤0.05)
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Figure 7. Details the proposed pathway where PKC‑ι acts on IKK α/β to release NF-κ B, causing IKK to be degraded and allowing NF-κ B to translocate to the
nucleus. PKC, protein kinase C: NF-κ B, nuclear factor-κ B; Iκ Bα, inhibitor of NF-κ Bα; IKK, Iκ Bα kinase.

following inhibitor treatments in the two PC cell lines, which
confirmed a reduction of NF-κ B translocation to the nuclei.
The phosphorylation of PTEN (S380) and AKT (S473) also
decreased significantly (P≤0.05) in the two PC cell lines, indicating that the AKT pathway also slowed down upon inhibitor
treatment.
Discussion
There has been increased interest in the status of aPKC‑ι, which
does not contain a Ca2+-binding region, has one zinc finger‑like
motif, and is the human homolog of the mouse PKC‑λ (31).
Eder et al (32) provided evidence for the role of PKC‑ι in cell
proliferation by demonstrating that increased protein levels of
PKC‑ι were associated with increased protein expression of
cyclin E and proliferation in ovarian cancer. Eder et al (32)
demonstrated in non-serous ovarian cancer that increased
protein levels of PKC‑ι markedly decreased overall survival
rate. PKC‑ι is critical for non-small cell lung cancer proliferation in vivo via activation of the Ras-related C3 botulinum toxin
substrate 1 (Rac1)/Rac1-activated kinase/mitogen-activated
protein kinase kinase 1,2/extracellular signal-regulated kinase
1,2 signaling pathway, which has been implicated in tumor cell
proliferation, indicating PKC‑ι as an oncogene in human nonsmall cell lung cancer (20,23). Additionally, the importance
of PKC‑ι is further recognized due to its exclusive association
with transformed phenotype of human melanomas in vivo and
in vitro (33), its overexpression in human non-small lung cancer
cell lines and cholangiocarcinoma (34), and its presence in the
transformed growth of the human lung adenocarcinoma A549
cell line in vitro and tumorigenicity in vivo (20). Our previous

study also highlighted the exclusive association of PKC‑ι with
the transformed phenotype of glioma and meningioma (35).
However, the linkage between the PKC family of proteins and
PC remains to be fully elucidated.
The results of the western blot analysis demonstrated
that the PKC‑ι protein was overexpressed in all PC tissues,
but not in BPH tissues (P=0.00048). Furthermore, the IHC
results demonstrated increased PKC‑ ι staining intensity
in PC glands compared with BPH glands and glands with
HGPIN. The BHP glands showed weak staining of PKC‑ι,
similar to samples obtained from patients with and without
prostatic adenocarcinoma. The stromal cells showed weak
to moderate staining of PKC‑ι in samples with and without
adenocarcinoma. It is possible that the reduced categorical
expression of PKC‑ ι observed in the comparison between
malignant and BPH tissues may be associated with the antigen
retrieval methodology of the IHC process in formalin-fixed,
archival specimens. The observation of marked and consistent
expression of PKC‑ι in all PC specimens and certain HGPIN
specimens is significant, as it may allow the prediction of the
proportion of HGPIN patients, estimated to be up to 50%, who
progress to clinical PC. The fact that benign prostatic acini
in patients with PC do not significantly express PKC‑ι further
underscores the histopathological dichotomy of the BPH and
PC pathways. Finally, if PKC‑ι is demonstrated to have be
significant in prostate carcinogenesis, it may offer an opportunity to target PKC‑ι in HGPIN patients for the prevention of
PC. The results of the present study suggested that PC showed
a higher dependency on PKC‑ι compared with non‑cancerous
prostate tissue. The increase in the expression of PKC‑ι may
be due to gene amplification or genetic duplication of PKC‑ι.
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Previous studies have shown that chromosome 3q26, where
PKC‑ι is located, is an amplicon and that gene amplification
of PKC‑ι is associated with non-small cell lung cancer and
esophageal squamous cell carcinoma (23,36). Studies have
also shown that PKC‑ι is co-amplified with neighboring gene
SRY-box 2 (37). These findings have clinical ramifications as
the increased expression of PKC‑ι has been shown to correlate
with poor prognosis in other types of cancer (32,34). The
results of the present study suggest that prostate cancer behaves
similarly and that increased expression of PKC‑ι indicates a
less favorable prognosis.
Although PKC‑ι has been previously shown to be involved
in the survival of the normal RWPE‑1 cell line, these results
were observed following serum starvation (38). As PKC‑ι is
activated under stress, for example, following the addition of
TNF‑α or serum starvation, and the results from the tissues
were so different, the present study examined the reliance
of cultured cell lines on PKC‑ι without serum starvation. It
was found that PKC‑ι had a significant effect in PC cells, but
had minimal effect in normal cells. This provided evidence
of the dependence of PC on PKC‑ι and assists in explaining
its overexpression in PC cells. As PKC‑ι can be a predictor
for PC (37) and is also an anti-apoptotic factor (39), resistance
to apoptosis is decreased by inhibiting PKC‑ι. The results of
the present study showed that inhibitors, including ICA‑1, may
not be directly toxic to cancer cells; however, by inhibiting
PKC‑ι, carcinoma cells that overexpress and rely on PKC‑ι
are profoundly affected. The WST‑1 results demonstrated that
the inhibitors had a cytostatic effect on the PC cells thereby
inhibiting their growth, differentiation and proliferation prior
to the induction of apoptosis.
It is suggested that PKC‑ι phosphorylates IKK, which in
turn releases the inhibitor Iκ Bα from NF-κ B, allowing NF-κ B
to translocate to the nucleus as a transcription factor known to
propagate cancer (Fig. 7). A previous study linked the activation of IKK through the action of PKC (38). The present study
showed that the phosphorylation of IKKα/β decreased upon
inhibition of PKC‑ι, which decreased the phosphorylation of
Iκ Bα and prevented its degradation by the release of activated
NF-κ B, allowing it to translocate into the nuclei. These data
suggest that, by inhibiting PKC‑ ι, the transcription factor
NF-κ B remained inhibited, and the chain of events was not
set in motion. NF-κ B is generally released during periods of
stress and is not the only pro-survival factor affecting the cell.
However, this pathway inhibition may explain the decrease
in cell growth rates for the two cell lines treated with PKC‑ι
inhibitors. In neuroblastoma cells, ICA‑1 has been shown to be
a specific inhibitor to PKC‑ι, and its inhibition has been shown
to induce apoptosis (24). In the present study, the DU‑145 cells
also showed signs of increased apoptotic markers and retarded
growth rate. The PC‑3 cells showed a similar decrease in
growth rate and were subject to apoptotic factors despite their
aggressive nature. One limitation of the present study was the
sample size of patient tissues used. A larger sample combined
with the in vivo assessment of the inhibitors is recommended.
In conclusion, the results in the present study suggested
that aPKCs are major components responsible for inducing
cell growth, differentiation and survival in human PC cells. In
addition, PKC‑ι was found to be involved in the activation and
nuclear translocation of NF-κ B. The results also suggested that
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ICA-and ACPD were effective aPKC inhibitors in PC cells and
did not affect normal prostate epithelial cells at the optimal
working concentrations for PC cells used. These inhibitors
reduced cell proliferation and induced the apoptosis of PC
cells. Taken together, these results indicate that the detection
of PKC‑ι may be used as a predictor of prostate carcinogenesis
and suggest that patients with PC may benefit from anti-PKC‑ι
therapy.
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